Munich Reinsurance Co Stock Corp in Munich Has $39.59 Million Holdings in AbbVie Inc. $ABBV

Key Points

• Munich Reinsurance increased its AbbVie position by 3.8% in the second quarter, acquiring 5,727 additional shares for a total of 157,348 shares valued at approximately $39.6 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie reported quarterly earnings of $3.65 per share and revenue of $16.99 billion, exceeding analyst estimates, while revenue rose 10.2% year over year. The company issued third-quarter EPS guidance of $3.84–$3.88.
• AbbVie recently paid a quarterly dividend of $1.73 per share, equivalent to a 2.7% yield, and analysts maintain a “Moderate Buy” consensus with an average price target of $275.73. Separately, EVP Nicholas Donoghoe sold 32,710 shares worth $8.18 million.

Munich Reinsurance Co Stock Corp in Munich grew its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 3.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 157,348 shares of the company's stock after purchasing an additional 5,727 shares during the quarter. Munich Reinsurance Co Stock Corp in Munich's holdings in AbbVie were worth $39,595,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ABBV. ACT Advisors LLC. raised its stake in AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock worth $425,000 after buying an additional 41 shares during the last quarter. Willner & Heller LLC lifted its holdings in AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock valued at $1,472,000 after buying an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC boosted its position in AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock valued at $359,000 after acquiring an additional 43 shares during the last quarter. Leslie Global Wealth LLC boosted its position in AbbVie by 1.5% during the second quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company's stock valued at $751,000 after acquiring an additional 44 shares during the last quarter. Finally, Bank of Jackson Hole Trust grew its holdings in AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company's stock worth $1,648,000 after acquiring an additional 44 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

Insider Activity at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.06% of the company's stock.

AbbVie Stock Performance

ABBV stock opened at $259.01 on Wednesday. The business has a 50-day simple moving average of $246.17 and a two-hundred day simple moving average of $226.63. The company has a market capitalization of $457.63 billion, a P/E ratio of 73.17, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. During the same period last year, the business earned $2.97 EPS. The business's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ABBV. Bank of America lifted their price objective on AbbVie from $234.00 to $276.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Evercore set a $235.00 target price on AbbVie in a research report on Friday, May 15th. Wells Fargo & Company lifted their target price on AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a report on Monday. Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. Finally, Canaccord Genuity Group increased their price target on AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $275.73.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source